Silence Therapeutics PLC (SLN NASDAQ) stock market data APIs
$3.7706
0.15(4%)
as of May 6, 2025
Silence Therapeutics PLC Financial Data Overview
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Prev. Close
3.7706
Open
3.9218
High
4.1297
Low
3.8406
52 wk Range
1.97-24.38
Market Cap
185 M
Shares Outstanding
47 225 K
Revenue
43 258 K
Beta
1.194
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Silence Therapeutics PLC data using free add-ons & libraries
Get Silence Therapeutics PLC Fundamental Data
Silence Therapeutics PLC Fundamental data includes:
- Net Revenue: 43 258 K
- EBITDA: -48 989 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-12-31
- EPS/Forecast: -0.2452
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Silence Therapeutics PLC News
New
Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying
We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against other takeover rum...
The 3 Best Gene Editing Stocks to Buy in August 2024
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030. Efficiencie...
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Wall Street likes to peer into the fog of the future and guess where a stock is headed. While these stock price predictions are based on educated estimates, often based on information and models unava...
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one. Viking Therapeutics (NASDAQ:VKTX) is the perfect example. Interest in w...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
